Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | GSK3A | P49840 | 4/20 | 0.31 |
| ▸ | GSK3B | P49841 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30440210 | 0.78 | RET (0.38) | GRM4CYP1A2GSK3AGSK3B | |
| SCHEMBL175432 | 0.78 | RET (0.38) | GRM4CYP1A2GSK3AGSK3B | |
| SCHEMBL14070089 | 0.77 | GRM4 (0.39) | GRM4CYP1A2GSK3AGSK3B | |
| SCHEMBL21128112 | 0.77 | PDK2 (0.35) | — | |
| SCHEMBL30242908 | 0.77 | GRM4 (0.32) | GRM4CYP1A2GSK3AGSK3B | |
| SCHEMBL14685108 | 0.77 | GRM4 (0.32) | GRM4CYP1A2GSK3AGSK3B | |
| SCHEMBL18921901 | 0.77 | CDK9 (0.35) | GSK3AGSK3B | |
| SCHEMBL9940853 | 0.77 | JAK2 (0.42) | GRM4 | |
| SCHEMBL13500372 | 0.77 | — | — | |
| SCHEMBL30806243 | 0.77 | GRM4 (0.39) | GRM4CYP1A2GSK3AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113354638-A | Preparation method of 5-fluoro-3-iodo-1H-pyrazolo [3,4-b ] pyridine | 天津敬康生物科技有限公司 | 2021-09-07 | — | — | CN | claimed |
| US-20260062411-A1 | NOVEL SALT OF SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND ITS USES | TORRENT PHARMACEUTICALS LTD (IN) | 2026-03-05 | — | — | US | disclosed |
| CN-116239593-B | Preparation method of vitamin Li Xigu intermediate | 上海裕兰生物科技有限公司 | 2025-05-02 | — | — | CN | disclosed |
| US-12064429-B2 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | ADVERIO PHARMA GMBH (DE) | 2024-08-20 | — | — | US | disclosed |
| CN-118388478-A | Pyrazole derivative and preparation method and application thereof | 河北科技大学 | 2024-07-26 | — | — | CN | disclosed |
| WO-2024038398-A1 | NOVEL SALT OF SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND ITS USES | TORRENT PHARMACEUTICALS LIMITED (IN) | 2024-02-22 | — | — | WO | disclosed |
| CN-117567461-A | Preparation method of vitamin Li Xigu intermediate | 佛山奕安赛医药科技有限公司 | 2024-02-20 | — | — | CN | disclosed |
| US-20230257398-A1 | PYRIMIDINE-BASED TRICYCLIC COMPOUND AND USE THEREOF | CHIA TAL TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
| CN-116239593-A | Preparation method of vitamin Li Xigu intermediate | 上海裕兰生物科技有限公司 | 2023-06-09 | — | — | CN | disclosed |
| US-20220409618-A1 | SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND THEIR USE | ADVERIO PHARMA GMBH (DE) | 2022-12-29 | — | — | US | disclosed |
| US-20120022084-A1 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-26 | — | — | US | disclosed |
| US-20120022084-A1 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-26 | — | — | US | disclosed |
| WO-2012004258-A1 | RING-FUSED PYRIMIDINES AND TRIAZINES AND USE THEREOF FOR THE TREATMENT AND/OR PROPHYLAXIS OF CARDIOVASCULAR DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012004259-A1 | RING-FUSED 4 -AMINOPYRIMIDINES AND USE THEREOF AS STIMULATORS OF SOLUABLE GUANYLATE CYCLASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012004259-A1 | RING-FUSED 4 -AMINOPYRIMIDINES AND USE THEREOF AS STIMULATORS OF SOLUABLE GUANYLATE CYCLASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012004258-A1 | RING-FUSED PYRIMIDINES AND TRIAZINES AND USE THEREOF FOR THE TREATMENT AND/OR PROPHYLAXIS OF CARDIOVASCULAR DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-12 | — | — | WO | disclosed |
| WO-2011161099-A1 | USE OF STIMULATORS AND ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE FOR TREATING SICKLE-CELL ANEMIA AND CONSERVING BLOOD SUBSTITUTES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-29 | — | — | WO | disclosed |
| WO-2011161099-A1 | USE OF STIMULATORS AND ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE FOR TREATING SICKLE-CELL ANEMIA AND CONSERVING BLOOD SUBSTITUTES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-29 | — | — | WO | disclosed |
| WO-2011147809-A1 | SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011147810-A1 | THE USE OF sGC STIMULATORS, sGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF SYSTEMIC SCLEROSIS (SSc). | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12064429-B2 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | PFKP, PON1, FABP3 | GRM4 2698/4885CYP1A2 125/4885GSK3A 3532/4885 |
| US-20230257398-A1 | PYRIMIDINE-BASED TRICYCLIC COMPOUND AND USE THEREOF | TYMP, TYMS, DPYD | GRM4 3853/4885CYP1A2 357/4885GSK3A 3203/4885 |
| US-20260062411-A1 | NOVEL SALT OF SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND ITS USES | PDE3B, PDE5A, PDE2A | GRM4 1206/4885CYP1A2 1788/4885GSK3A 982/4885 |
| US-20220409618-A1 | SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND THEIR USE | PFKP, PON1, FABP3 | GRM4 2698/4885CYP1A2 125/4885GSK3A 3532/4885 |
| US-20120022084-A1 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | PFKP, PON1, FABP3 | GRM4 2698/4885CYP1A2 125/4885GSK3A 3532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.